Clinical application of ultrasound-guided percutaneous microwave ablation for benign breast lesions: a prospective study.
Adolescent
Adult
Aged
Biopsy
Breast
/ diagnostic imaging
Breast Neoplasms
/ diagnostic imaging
Feasibility Studies
Female
Follow-Up Studies
Humans
Male
Microwaves
/ adverse effects
Middle Aged
Prospective Studies
Radiofrequency Ablation
/ adverse effects
Retreatment
/ statistics & numerical data
Treatment Outcome
Ultrasonography, Interventional
Young Adult
Benign breast lesion
Efficiency
Microwave ablation
Safety
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
11 Apr 2019
11 Apr 2019
Historique:
received:
13
12
2018
accepted:
25
03
2019
entrez:
13
4
2019
pubmed:
13
4
2019
medline:
14
8
2019
Statut:
epublish
Résumé
Background: Benign breast lesions are the most common diseases in adult women, which have been treated with minimally invasive therapies in recent years. Little is known about the feasibility of Microwave ablation (MWA) for benign breast lesion treatment. The primary aim of this prospective study was to evaluate the safety and efficiency of MWA as a potential therapeutic option for benign breast lesions in a single-center cohort study. Women with possibly benign breast lesions based on an ultrasound (US) assessment who were scheduled to undergo MWA between November 2014 to July 2018 were included in the study. The patients underwent conventional US to measure the size of the lesion, Doppler US to assess the vascularity of the lesion, elastography to evaluate the stiffness of the mass, core needle biopsy of suspicious lesions, contrast-enhanced US to help determine the treatment plan and eventually MWA of the lesion. Lesions were followed at one, three, six, twelve and eighteen months after treatment to with the same imaging modalities. A total of 314 women aged 17 to 69 years old (mean = 36.9 ± 9.9 years) with 725 benign breast lesions (mean of maximum diameter = 10.86 ± 5.40 mm) were included. The frequency of palpable mass, pain and nipple discharge significantly decreased after treatment. Complete ablation rate was 97.8%, immediately after ablation, which increased to 100% after supplementary ablation of the 15 cases with incomplete ablation. Blood flow classification and lesion's volume also showed a significant decrease, while both volume reduction ratio and disappearance rate significantly increased following treatment. The elasticity score of the lesions showed fluctuations across different follow-up intervals. None of the patients experienced major complications and the 1% who had mild symptoms were successfully treated. MWA treatment is shown to be safe and efficient and has the potential to be considered as an alternative first line treatment for benign breast lesions.
Sections du résumé
BACKGROUND
BACKGROUND
Background: Benign breast lesions are the most common diseases in adult women, which have been treated with minimally invasive therapies in recent years. Little is known about the feasibility of Microwave ablation (MWA) for benign breast lesion treatment. The primary aim of this prospective study was to evaluate the safety and efficiency of MWA as a potential therapeutic option for benign breast lesions in a single-center cohort study.
METHODS
METHODS
Women with possibly benign breast lesions based on an ultrasound (US) assessment who were scheduled to undergo MWA between November 2014 to July 2018 were included in the study. The patients underwent conventional US to measure the size of the lesion, Doppler US to assess the vascularity of the lesion, elastography to evaluate the stiffness of the mass, core needle biopsy of suspicious lesions, contrast-enhanced US to help determine the treatment plan and eventually MWA of the lesion. Lesions were followed at one, three, six, twelve and eighteen months after treatment to with the same imaging modalities.
RESULTS
RESULTS
A total of 314 women aged 17 to 69 years old (mean = 36.9 ± 9.9 years) with 725 benign breast lesions (mean of maximum diameter = 10.86 ± 5.40 mm) were included. The frequency of palpable mass, pain and nipple discharge significantly decreased after treatment. Complete ablation rate was 97.8%, immediately after ablation, which increased to 100% after supplementary ablation of the 15 cases with incomplete ablation. Blood flow classification and lesion's volume also showed a significant decrease, while both volume reduction ratio and disappearance rate significantly increased following treatment. The elasticity score of the lesions showed fluctuations across different follow-up intervals. None of the patients experienced major complications and the 1% who had mild symptoms were successfully treated.
CONCLUSION
CONCLUSIONS
MWA treatment is shown to be safe and efficient and has the potential to be considered as an alternative first line treatment for benign breast lesions.
Identifiants
pubmed: 30975107
doi: 10.1186/s12885-019-5523-6
pii: 10.1186/s12885-019-5523-6
pmc: PMC6458746
doi:
Types de publication
Journal Article
Langues
eng
Pagination
345Subventions
Organisme : Science and Technology Bureau of Nanning, Guangxi, China
ID : 20143163
Références
Cancer. 2001 Oct 15;92(8):2036-44
pubmed: 11596017
AJR Am J Roentgenol. 2001 Dec;177(6):1459-63
pubmed: 11717107
AJR Am J Roentgenol. 2002 May;178(5):1147-51
pubmed: 11959720
Am J Surg. 2002 Oct;184(4):359-63
pubmed: 12383903
Ann Surg Oncol. 2004 Feb;11(2):139-46
pubmed: 14761916
Radiology. 2004 Apr;231(1):215-24
pubmed: 14990810
Ann Surg Oncol. 2004 May;11(5):542-9
pubmed: 15123465
Radiology. 2006 May;239(2):341-50
pubmed: 16484352
J Am Coll Surg. 2006 Jul;203(1):54-63
pubmed: 16798487
Ultrasound Med Biol. 2007 Nov;33(11):1736-49
pubmed: 17629608
World J Surg Oncol. 2007 Oct 29;5:124
pubmed: 17967193
J Ultrasound Med. 2008 Jan;27(1):65-73
pubmed: 18096732
Clin Radiol. 2009 Apr;64(4):381-5
pubmed: 19264182
Radiology. 2009 May;251(2):339-46
pubmed: 19304918
Eur Radiol. 2010 Apr;20(4):886-97
pubmed: 19760231
Ultraschall Med. 2010 Apr;31(2):156-62
pubmed: 19941254
Breast Cancer. 2011 Apr;18(2):124-8
pubmed: 19943129
Ann Surg Oncol. 2010 Apr;17(4):1076-93
pubmed: 20033319
Immunol Invest. 2010;39(1):74-92
pubmed: 20064086
Breast Cancer. 2011 Jan;18(1):10-7
pubmed: 20072824
Int J Cancer. 2011 Jun 1;128(11):2653-62
pubmed: 20715115
Int J Cancer. 2011 Oct 15;129(8):1970-8
pubmed: 21154744
Cardiovasc Intervent Radiol. 2012 Aug;35(4):914-20
pubmed: 21833802
Ultrasound Med Biol. 1990;16(6):553-9
pubmed: 2238263
Radiology. 2012 May;263(2):364-73
pubmed: 22438362
Jpn J Radiol. 2012 Jul;30(6):533-9
pubmed: 22528338
Acta Radiol. 2012 Oct 1;53(8):852-6
pubmed: 22961645
Eur J Surg Oncol. 2013 Dec;39(12):1317-24
pubmed: 24139998
Breast Care (Basel). 2013 Oct;8(5):356-60
pubmed: 24415989
Insights Imaging. 2014 Apr;5(2):209-16
pubmed: 24563244
Mayo Clin Proc. 2014 Apr;89(4):536-47
pubmed: 24684875
Eur J Radiol. 2014 Oct;83(10):1771-7
pubmed: 25043496
Semin Intervent Radiol. 2014 Jun;31(2):193-202
pubmed: 25049447
Gland Surg. 2014 May;3(2):142-8
pubmed: 25083508
Eur J Surg Oncol. 2014 Oct;40(10):1222-9
pubmed: 25108815
Korean J Radiol. 2014 Nov-Dec;15(6):836-43
pubmed: 25469097
PLoS One. 2015 Mar 23;10(3):e0120303
pubmed: 25799220
Abdom Radiol (NY). 2016 Aug;41(8):1511-21
pubmed: 26969495
Int J Hyperthermia. 2017 May;33(3):263-270
pubmed: 27809612
Eur Radiol. 2017 Aug;27(8):3199-3210
pubmed: 28050693
J Ther Ultrasound. 2017 Jul 3;5:18
pubmed: 28680636
Oncotarget. 2017 May 23;8(45):79376-79386
pubmed: 29108316
J Thorac Dis. 2017 Nov;9(11):4767-4773
pubmed: 29268548